The results indicate that the CPR complex interrupts the endosomal pathway, effectively reducing the colocalization of delivered siRNA with lysosomes and enhancing gene regulation efficiency, suggesting that the CPR nanocarrier design could serve as a versatile platform for targeted RNA delivery.
Abstract
ABSTRACT Small interfering RNA (siRNA) has shown great potential for treating various genetic diseases, but lysosomal degradation limits its bioavailability. Here, we present the design of a Channel‐PNA‐siRNA (CPR) complex that facilitates endosomal escape by actively inducing osmotic rupture of the endosomes. Our design utilizes the transmembrane domain of the M2 proton channel (M2TM) to facilitate proton influx into the liposome while serving as an anchor for siRNA; this surface tethering is mediated by a peptide nucleic acid (PNA) linker that enables stable, non‐covalent binding. Our results indicate that the CPR complex interrupts the endosomal pathway, effectively reducing the colocalization of delivered siRNA with lysosomes and enhancing gene regulation efficiency. Furthermore, we demonstrate dual‐target gene knockdown using CPR‐tethered liposomes by encapsulating additional siRNAs in the empty cavity of the liposome. These findings highlight the therapeutic potential of modulating the endosomal pH environment to prevent lysosomal degradation, suggesting that the CPR nanocarrier design could serve as a versatile platform for targeted RNA delivery.
Molecular simulations are employed to elucidate how LNPs fuse with the endosomal membrane and release their payloads, and identify multiple fusion pathways, with a dominant stalk-pore mechanism.
A. P. Singh, Kana Shibata, Yusuke Miyazaki et al.· bioRxiv· 0 citations
A synthetic ionizable lipid with a dual pKa property that is retained in formulated LNPs is introduced and it is shown that after intravenous injection, these dual pKa LNPs produce lung‐selective mRNA expression with higher potency than a cationic lipid‐rich comparator while remaining well tolerated.
Seong Gi Lim, Min-Ju Lee, Yiming Wang et al.· Advancement of science· 0 citations
The optimized nanocarrier promoted efficient uptake of fluorescent siRNA in MDA-MB-231 cells and achieved functional delivery of anti-EGFR, leading to substantially reduced expression of the target gene at both transcript and protein levels.
P. Białecki, S. Braccia, T. Makowski et al.· bioRxiv· 0 citations
Small interfering RNA (siRNA) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated Protein 9 (Cas9) complexes are effective approaches to temporarily downregulate protein expression via post-transcription RNA interference or permanently altering protein expression via editing gen...
Abdulelah Alhazza, Sorour Khayyatnejad Shoushtari, Hasan Uludağ et al.· Frontiers in Nanotechnology· 0 citations
Small interfering RNA (siRNA) therapeutics have emerged as a transformative approach for sequence-specific gene silencing, offering the potential to treat a broad spectrum of diseases by selectively suppressing disease-associated genes. However, the clinical translation of siRNA remains limited by rapid enzymatic degra...
G. S. Amrish Varshan, S. Namasivayam· Nanomedicine: Nanotechnology...· 0 citations
It is shown that introducing a pH-sensitive linker in C16 lipid- and C22 lipid-conjugated ASOs increases endosomal remodeling events detected via a Galectin 9 reporter imaging assay, despite similar levels of ASO cellular uptake, and incorporation of a pH-sensitive linker can lead to improved gene silencing in vitro.
Priyanka Mangla, Emma Kay, M. J. Munson et al.· Nucleic Acid Therapeutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.